Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

PartnershipUlixacaltamidePositive

AI Analysis

Summary

Praxis Precision Medicines and Remagine Labs announced a strategic collaboration to develop a transdermal formulation of ulixacaltamide for the treatment of essential tremor.

Importance:6/10

Sentiment:

0.60

partnershipcollaborationtransdermalessential_tremordrug_development

Related Companies

$PRAX

Read the original article

Published by yahoo_finance on July 7, 2026 12:00 PM

Read Original